Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Acta Physiol (Oxf). 2019 Mar 13;226(3):e13267. doi: 10.1111/apha.13267

Figure 3. Adjunctive mitoprotection improved renal function in renovascular hypertension (RVH).

Figure 3.

A: Over 3 months, estimated glomerular filtration rate (eGFR) increased only in RVH patients treated with percutaneous transluminal renal angioplasty (PTRA) and elamipretide (ELAM). B: Treatment with ELAM (but not placebo) during PTRA decreased systolic blood pressure 3 months after revascularization. C: Delta change in urinary COX3 and ND1 within 24hrs of PTRA correlated inversely with the change in IGFBP-7 × TIMP-2 levels of 24hrs. D: Only delta change in urinary COX3 correlated with the change in eGFR of 3 months after PTRA.